Noopept vs Selank
Same Russian pharmacology tradition, different jobs: Noopept was developed for cognition, Selank as an anxiolytic. Both have human data that stops well short of Western standards.
Short answer
Noopept and Selank both have human clinical data, so the deciding factor is what you want them for. Noopept suits someone focused on cognition and memory, while Selank is aimed at anxiety and focus. The headline human result for Noopept is benefit comparable to piracetam in small Russian trials in mild cognitive impairment; no placebo-controlled Western trial.
Noopept
A piracetam-analog dipeptide that raises NGF/BDNF in animals; the human data is small, single-country Russian trials — real but unreplicated to Western standards, and it's unapproved in the US.
Full Noopept evidence reviewSelank
A GABA-modulating anxiolytic that matched benzodiazepines in small Russian trials; the mechanism is credible but the evidence base is thin and single-country.
Full Selank evidence reviewNoopept vs Selank: head to head
- FDA status / approved use
Noopept
Registered drug in Russia and nearby countries; not FDA-approved; no approved use in the US or EUSelank
Reportedly past Phase III in Russia; not FDA-approved; sold in the US as a research peptide- Marketed for
Noopept
Cognition, memorySelank
Anxiety, focus- Outcome areas
Noopept
Cognitive function / memorySelank
Mood / anxiety / stress; Cognitive function / memory- Evidence grade
Noopept
Clinical dataSelank
Clinical data- How it works
Noopept
Raises the brain growth proteins NGF and BDNF in rat studiesSelank
Modulates the GABA system without acting as a benzodiazepine- Route and dosing
Noopept
OralSelank
Nasal spray (intranasal)- Headline human result
Noopept
Benefit comparable to piracetam in small Russian trials in mild cognitive impairment; no placebo-controlled Western trialSelank
Matched benzodiazepines on anxiety in small Russian trials (n=62 vs medazepam), none described as randomized- Strongest evidence
Noopept
Neznamov, Neurosci Behav Physiol 2009Noopept evidence reviewPubMed 19234797Selank
Medvedev, Korsakov J 2015Selank evidence reviewPubMed 26356395- Key safety signal
Noopept
No long-term safety data; US products have unverified contentSelank
No large human safety database; lab work showed anti-clotting activity, a theoretical bleeding concern- How it is obtained
Noopept
Sold gray-market as a research chemical; no approved or legitimately compounded human productSelank
Sold gray-market as a research chemical; no approved or legitimately compounded human product
| Noopept | Selank | |
|---|---|---|
| FDA status / approved use | Registered drug in Russia and nearby countries; not FDA-approved; no approved use in the US or EU | Reportedly past Phase III in Russia; not FDA-approved; sold in the US as a research peptide |
| Marketed for | Cognition, memory | Anxiety, focus |
| Outcome areas | Cognitive function / memory | Mood / anxiety / stress; Cognitive function / memory |
| Evidence grade | Clinical data | Clinical data |
| How it works | Raises the brain growth proteins NGF and BDNF in rat studies | Modulates the GABA system without acting as a benzodiazepine |
| Route and dosing | Oral | Nasal spray (intranasal) |
| Headline human result | Benefit comparable to piracetam in small Russian trials in mild cognitive impairment; no placebo-controlled Western trial | Matched benzodiazepines on anxiety in small Russian trials (n=62 vs medazepam), none described as randomized |
| Strongest evidence | Neznamov, Neurosci Behav Physiol 2009Noopept evidence reviewPubMed 19234797 | Medvedev, Korsakov J 2015Selank evidence reviewPubMed 26356395 |
| Key safety signal | No long-term safety data; US products have unverified content | No large human safety database; lab work showed anti-clotting activity, a theoretical bleeding concern |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Sold gray-market as a research chemical; no approved or legitimately compounded human product |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Neither is FDA-approved and neither has a large, blinded, placebo-controlled trial. Noopept's human record is small Russian studies in mild cognitive impairment of vascular and post-traumatic origin, run against piracetam as comparator; Selank's is small Russian studies in anxiety disorders, run against benzodiazepines and not described as randomized or blinded. Both are sold in the US as unregulated products rather than the trialed drug, and the two have never been compared with each other.
Noopept fits if
Noopept is the relevant read if cognitive symptoms and the racetam-adjacent nootropic literature are the thread you are pulling.
Selank fits if
Selank is the relevant read if anxiety is the question and you want to understand a non-benzodiazepine, GABA-modulating mechanism.
Noopept vs Selank: common questions
- Is either Noopept or Selank FDA-approved?
- No. Noopept is a registered drug in Russia and nearby countries; not FDA-approved; no approved use in the US or EU. Selank is reportedly past Phase III in Russia; not FDA-approved; sold in the US as a research peptide.
- Which has stronger human evidence, Noopept or Selank?
- Neither clearly. Both have human clinical data. The key source for Noopept is Neznamov, Neurosci Behav Physiol 2009; for Selank, it is Medvedev, Korsakov J 2015.
- What are the main safety concerns with Noopept and Selank?
- Noopept has no long-term safety data; US products have unverified content. Selank has no large human safety database; lab work showed anti-clotting activity, a theoretical bleeding concern.
Key studies behind each
Noopept
- Ostrovskaya RU, et al. (2002). The original novel nootropic and neuroprotective agent noopept. Eksp Klin Farmakol. PubMed 12596521
- Ostrovskaya RU, Gudasheva TA, Voronina TA, et al. (2010). On the mechanism of noopept action: decrease in activity of stress-induced kinases and increase in expression of neutrophines. Eksp Klin Farmakol. PubMed 21395007
- Ostrovskaya RU, et al. (2008). Noopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by beta-amyloid25-35 injection). Bull Exp Biol Med. PubMed 19145356
- Kondratenko RV, Derevyagin VI, Skrebitsky VG. (2010). Novel nootropic dipeptide Noopept increases inhibitory synaptic transmission in CA1 pyramidal cells. Neurosci Lett. PubMed 20382202
Selank
- Vyunova TV, Andreeva L, Shevchenko K, et al. (2018). Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. PubMed 30255741
- Volkova A, Shadrina M, Kolomin T, et al. (2016). Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. PubMed 26924987
- Zozulya AA, Kost NV, Sokolov OYu, et al. (2001). The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. PubMed 11550013
- Doyno CR, White CM. (2021). Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. J Clin Pharmacol. PubMed 34396551
The full evidence reviews
- Noopept: a potent Russian dipeptide nootropic with a thin clinical base
A proline-containing dipeptide analog of piracetam that raises NGF and BDNF in animal studies and is a registered drug in Russia. The mechanism is credible — but the human evidence is small, single-country, and unreplicated to Western standards.
Updated August 2026
- Selank: a non-benzodiazepine anxiolytic peptide, lightly tested
A tuftsin-analog heptapeptide that modulates GABA without being a benzodiazepine — and matched benzodiazepines in small Russian trials. The mechanism is credible; the evidence base is thin.
Updated August 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm Noopept availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: ImmortalsLumoraLunaRxMavesMetoNava Health